Both cohorts 2 and 3 were negative for I BCR-ABL1 i KD mutation by SS. Patients with clinically relevant I BCR-ABL1 i KD mutation detected by NGS in cohorts 1 and 3 were also longitudinally followed-up by SS during subsequent time points at least once in 6 months. Of the 41 CML patients who did not achieve MMR at 12-18 months post imatinib therapy (cohort-3) screened for I BCR-ABL1 i KD mutation by NGS, 20 mutations were detected in 12 patients. In a patient with F317L mutation (VAF: 15.83%), SS detected the same mutation after 12 months whereas the rest of the low-level mutations were not identified in the subsequent follow-up samples in the remaining 6 patients. [Extracted from the article]